Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 20, 2024 05:41 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial

Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial...
December 18, 2024 08:59 ET | Source: Novo Nordisk A/S

The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed

Bagsværd, Denmark, 18 December 2024 — Today, Novo Nordisk completed its acquisition of three manufacturing sites from Novo Holdings A/S. The completion follows the finalisation of Novo Holdings’...
December 16, 2024 07:52 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 16 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
December 16, 2024 01:29 ET | Source: Novo Nordisk A/S

Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark

Bagsværd, Denmark, 16 December 2024 – Today, Novo Nordisk announced plans to invest 8.5 billion Danish kroner to establish a completely new production facility in Odense, Denmark. The investment marks...
December 14, 2024 00:08 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close

Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S’s pending acquisition of Catalent, Inc. (Catalent), including expiry of...
December 12, 2024 08:47 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease-related events

Bagsværd, Denmark, 12 December 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for...
December 09, 2024 10:43 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 9 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
December 06, 2024 13:11 ET | Source: Novo Nordisk A/S

The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings

Bagsværd, Denmark, 6 December 2024 — Today, the European Commission approved Novo Holdings A/S’ acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation...
December 03, 2024 08:00 ET | Source: Novo Nordisk A/S

Novo Nordisk to present new data from sickle cell disease and haemophilia trials at the 66th American Society of Hematology (ASH) annual meeting

HIBISCUS phase 2 data evaluating the safety profile and efficacy of etavopivat in adult and adolescent patients with sickle cell diseaseFRONTIER4 interim phase 3 results evaluating safety profile and...
December 02, 2024 06:46 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 2 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...